| NCT ID | NCT06521944 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CorEvitas |
| Condition | Respiratory Syncytial Virus (RSV) |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,062 participants |
| Start Date | 2024-06-28 |
| Primary Completion | 2030-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,062 participants in total. It began in 2024-06-28 with a primary completion date of 2030-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The research question is: What is the risk of adverse pregnancy outcomes, including preterm birth, hypertensive disorders, and other maternal and neonatal/infant outcomes, following exposure to RSV vaccine between 32 weeks, 0 days and 36 weeks, 6 days of gestation in the CorEvitas Respiratory Syncytial Virus Vaccine Pregnancy Registry (RSV-PR)? The primary study objective is to estimate the risk of (1) preterm birth and (2) hypertensive disorders following exposure to RSV vaccine between 32 weeks, 0 days and 36 weeks, 6 days of gestation. The secondary study objective is to estimate the risk of other safety outcomes of interest following exposure to RSV vaccine between 32 weeks, 0 days and 36 weeks, 6 days of gestation, including: * Pregnancy-related outcomes: stillbirth, premature labor, premature rupture of membranes, preterm premature rupture of membranes, cesarean delivery, prolonged maternal duration of hospital stay * Maternal outcomes: thrombocytopenia, Guillain-Barré syndrome, other immune-mediated demyelinating conditions, polyneuropathies, atrial fibrillation, maternal death * Neonatal/infant outcomes: small for gestational age, large for gestational age, low birth weight, admission to a neonatal intensive care unit (NICU), NICU duration of stay, mechanical ventilation in neonatal period, neonatal death, postnatal growth at 1 year of age The exploratory study objective is to describe the most frequently reported maternal adverse events following exposure to RSV vaccine between 32 weeks, 0 days and 36 weeks, 6 days of gestation.
Eligibility Criteria
Inclusion Criteria: * Individuals must meet the following inclusion criteria to be eligible for inclusion in the study: 1. A resident of the US at enrollment 2. 18 to 50 years of age at enrollment 3. Gestational age of ≥32 weeks, 0 days at enrollment 4. If exposed to RSV vaccine, receipt of any RSV vaccine between 32 weeks, 0 days and 36 weeks, 6 days of gestation 5. Evidence of a personally signed and dated informed consent document or, upon waiver of written consent by the relevant IRB/independent ethics committee, verbal consent indicating that the individual (or a legally acceptable representative) has been informed of all pertinent aspects of the study 6. Authorization obtained for the relevant HCP(s) to provide data to the registry 7. Contact information available (for participant and HCPs) Exclusion Criteria: * Individuals meeting any of the following criteria will not be included in the study: 1. Receipt of an RSV vaccine during pregnancy before 32 weeks, 0 days gestation 2. Multi-fetal pregnancy 3. Enrolled in the RSV-PR with a previous pregnancy
Contact & Investigator
Ronna Chan, PhD, MPH
PRINCIPAL INVESTIGATOR
PPD, Part of Thermo Fisher Scientific
Frequently Asked Questions
Who can join the NCT06521944 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Respiratory Syncytial Virus (RSV). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06521944 currently recruiting?
Yes, NCT06521944 is actively recruiting participants. Contact the research team at RSV@corevitas.com for enrollment information.
Where is the NCT06521944 trial being conducted?
This trial is being conducted at Wilmington, United States.
Who is sponsoring the NCT06521944 clinical trial?
NCT06521944 is sponsored by CorEvitas. The principal investigator is Ronna Chan, PhD, MPH at PPD, Part of Thermo Fisher Scientific. The trial plans to enroll 2,062 participants.